Circulating Tumor DNA as Biomarkers for Cancer Detection

Detection of circulating tumor DNAs (ctDNAs) in cancer patients is an important component of cancer precision medicine ctDNAs. Compared to the traditional physical and biochemical methods, blood-based ctDNA detection offers a non-invasive and easily accessible way for cancer diagnosis, prognostic determination, and guidance for treatment. While studies on this topic are currently underway, clinical translation of ctDNA detection in various types of cancers has been attracting much attention, due to the great potential of ctDNA as blood-based biomarkers for early diagnosis and treatment of cancers. ctDNAs are detected and tracked primarily based on tumor-related genetic and epigenetic alterations. In this article, we reviewed the available studies on ctDNA detection and described the representative methods. We also discussed the current understanding of ctDNAs in cancer patients and their availability as potential biomarkers for clinical purposes. Considering the progress made and challenges involved in accurate detection of specific cell-free nucleic acids, ctDNAs hold promise to serve as biomarkers for cancer patients, and further validation is needed prior to their broad clinical use.

[1]  James N Ingle,et al.  Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. , 2010, Human pathology.

[2]  Daniel F. Hayes,et al.  ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients , 2015, Clinical Cancer Research.

[3]  Katarzyna Sikora,et al.  Evaluation of cell-free DNA as a biomarker for pancreatic malignancies , 2015, The International journal of biological markers.

[4]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[5]  D D Zhou,et al.  Sperm quality and DNA damage in men from Jilin Province, China, who are occupationally exposed to ionizing radiation. , 2016, Genetics and molecular research : GMR.

[6]  Bruno Landi,et al.  Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.

[7]  Jian Gu,et al.  Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. , 2013, Cancer research.

[8]  Nicholas Dainiak.  Inferences, Risk Modeling, and Prediction of Health Effects of Ionizing Radiation , 2016, Health physics.

[9]  Qinghua Zhou,et al.  Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Brigitte Rack,et al.  DNA methylation markers for early detection of women's cancer: promise and challenges. , 2014, Epigenomics.

[11]  Lizhong Dai,et al.  Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing , 2016, Tumor Biology.

[12]  Peter Ulz,et al.  Circulating tumor DNA as a liquid biopsy for cancer. , 2015, Clinical chemistry.

[13]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[14]  V. Levenson,et al.  Methylation patterns in cell‐free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients , 2011, International journal of cancer.

[15]  Bela Molnar,et al.  Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. , 2006, Gastroenterology.

[16]  Bruno Landi,et al.  Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[17]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[18]  Olivier Lantz,et al.  Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients , 2015, International journal of cancer.

[19]  Wen-Shyong Tzou,et al.  Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers , 2004, World Journal of Surgery.

[20]  Chien-Hua Huang,et al.  Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients. , 2012, Resuscitation.

[21]  Nguyen Tien Huy,et al.  Elevated Levels of Cell-Free Circulating DNA in Patients with Acute Dengue Virus Infection , 2011, PloS one.

[22]  W. Lau,et al.  Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.

[23]  Savitri Krishnamurthy,et al.  The emerging role of circulating tumor cells in breast cancer , 2012, Cancer cytopathology.

[24]  Janusz Milanowski,et al.  Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report , 2014, Medical Oncology.

[25]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[26]  A. Goldkorn,et al.  Circulating Tumor Cells in Prostate Cancer , 2013, Cancers.

[27]  Kiyofumi Yamada,et al.  Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. , 2012, Biochemical and biophysical research communications.

[28]  F. A. Benko,et al.  Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. , 1997, British Journal of Cancer.

[29]  Robert J. Schmitz,et al.  MethylC-seq library preparation for base-resolution whole-genome bisulfite sequencing , 2015, Nature Protocols.

[30]  Yi Zhang,et al.  Single-tube analysis of DNA methylation with silica superparamagnetic beads. , 2010, Clinical chemistry.

[31]  Wendy (Shuwen) He,et al.  The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer , 2016, Expert review of molecular diagnostics.

[32]  Niels Pallisgaard,et al.  Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan , 2012, Clinical Cancer Research.

[33]  R. Okuyama,et al.  Quantitative analysis of the BRAFV600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR , 2016, International Journal of Clinical Oncology.

[34]  Torunn I Yock,et al.  Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. , 2012, Cancer research.

[35]  Paul Cairns,et al.  Gene methylation and early detection of genitourinary cancer: the road ahead , 2007, Nature Reviews Cancer.

[36]  John A. Foekens,et al.  Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen , 2016, Oncotarget.

[37]  Thomas Thum,et al.  Exosomes: new players in cell-cell communication. , 2012, The international journal of biochemistry & cell biology.

[38]  E. O’Neill,et al.  Clinical utility of RASSF1A methylation in human malignancies , 2015, British Journal of Cancer.

[39]  Ash A. Alizadeh,et al.  Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. , 2015, Seminars in radiation oncology.

[40]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[41]  Jing Yi,et al.  Detection of aberrant p16 methylation in the serum of colorectal cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  A. Bardelli,et al.  Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.

[43]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[44]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[45]  Peter Molloy,et al.  Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. , 2002, Methods.

[46]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[47]  Li Jiao,et al.  K-ras Mutation and p16 and Preproenkephalin Promoter Hypermethylation in Plasma DNA of Pancreatic Cancer Patients: In Relation to Cigarette Smoking , 2007, Pancreas.

[48]  Bo Li,et al.  Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. , 2006, Clinical biochemistry.

[49]  A. Gazdar,et al.  DNA methylation based biomarkers in non-invasive cancer screening. , 2010, Current molecular medicine.

[50]  T. Ruers,et al.  Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  Jérôme Alexandre Denis,et al.  Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery , 2016, Molecular oncology.

[52]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[53]  Cheng Qian,et al.  Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer , 2016, Oncotarget.

[54]  Martin Widschwendter,et al.  Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.

[55]  Shinzaburo Noguchi,et al.  Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay , 2012, Breast Cancer Research and Treatment.

[56]  Peter Ulz,et al.  Circulating tumor cells and DNA as liquid biopsies , 2013, Genome Medicine.

[57]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Amal Fawzy,et al.  Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer , 2016, Tumor Biology.

[59]  D. Clayton,et al.  Genome-wide association studies: theoretical and practical concerns , 2005, Nature Reviews Genetics.

[60]  Shinzaburo Noguchi,et al.  Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients , 2015, SpringerPlus.

[61]  N. Navin,et al.  Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.

[62]  Larissa V Furtado,et al.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. , 2015, The Journal of molecular diagnostics : JMD.

[63]  J. Lutterbaugh,et al.  Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. , 2001, Cancer research.

[64]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[65]  S. McGuire.  World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.

[66]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  K. Sikaris,et al.  CA125--a test with a change of heart. , 2011, Heart, lung & circulation.

[68]  Huanming Yang,et al.  The DNA Methylome of Human Peripheral Blood Mononuclear Cells , 2010, PLoS biology.

[69]  Hendee Wr,et al.  Health effects of exposure to low-level ionizing radiation. , 1998 .

[70]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[71]  Karen Page,et al.  Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. , 2012, Genome research.

[72]  Marie-Cécile Le Deley,et al.  Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial , 2016, Clinical Cancer Research.

[73]  P. Deloukas,et al.  A Comparison of the Whole Genome Approach of MeDIP-Seq to the Targeted Approach of the Infinium HumanMethylation450 BeadChip® for Methylome Profiling , 2012, PloS one.

[74]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[75]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[76]  V. Wong,et al.  Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients , 2015, Proceedings of the National Academy of Sciences.

[77]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[78]  R. Strausberg,et al.  Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  Peiyong Jiang,et al.  Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. , 2013, Clinical chemistry.

[80]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[81]  Ash A. Alizadeh,et al.  Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq , 2015, Expert review of molecular diagnostics.

[82]  Jianhui Guo,et al.  Mutations in the Human naked cuticle Homolog NKD1 Found in Colorectal Cancer Alter Wnt/Dvl/β-Catenin Signaling , 2009, PloS one.

[83]  A. Feinberg,et al.  DNA methylation in cancer: three decades of discovery , 2014, Genome Medicine.

[84]  Jorge S. Reis-Filho,et al.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer , 2013, Nature Reviews Clinical Oncology.

[85]  A Ruibal Morell,et al.  CEA serum levels in non-neoplastic disease. , 1992, The International journal of biological markers.

[86]  Andre Marziali,et al.  Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform , 2014, Oncotarget.

[87]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[88]  Keitaro Matsuo,et al.  Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  Tza-Huei Wang,et al.  The promise of methylation on beads for cancer detection and treatment , 2014, Expert review of molecular diagnostics.

[90]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[91]  R. Rosell,et al.  Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[93]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[94]  G. Poston,et al.  Biopsy of solid liver tumors: adverse consequences. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.

[95]  S. Murphy,et al.  Methylation-specific PCR. , 2013, Methods in molecular biology.

[96]  M. Provencio,et al.  Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients , 1999, British Journal of Cancer.

[97]  Alan Ashworth,et al.  Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR , 2013, Clinical Cancer Research.

[98]  J Martin,et al.  Exon 3 β-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome , 2005, Gut.

[99]  Xianshu Gao,et al.  "Liquid biopsy"-ctDNA detection with great potential and challenges. , 2015, Annals of translational medicine.

[100]  Gary D Bader,et al.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.

[101]  Antonio C. Wolff,et al.  Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer , 2014, Clinical Cancer Research.

[102]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[103]  Rodrigo Dienstmann,et al.  Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test , 2015, Molecular oncology.

[104]  Qinghua Feng,et al.  Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[107]  Larissa V Furtado,et al.  Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer , 2011, BMC medicine.

[108]  W. Morgan,et al.  Non-targeted Effects Induced by Ionizing Radiation: Mechanisms and Potential Impact on Radiation Induced Health Effects Cancer Letters , 2022 .

[109]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[110]  Klaus Pantel,et al.  Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. , 2011, Molecular bioSystems.

[111]  James R. Eshleman,et al.  Isaac Kinde Endometrial Cancers Evaluation of DNA from the Papanicolaou Test to Detect Ovarian , 2013 .

[112]  Ugo Boggi,et al.  High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer , 2012, PloS one.

[113]  I. Hudecova,et al.  Digital PCR analysis of circulating nucleic acids. , 2015, Clinical biochemistry.

[114]  M Monden,et al.  Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  G. Samimi,et al.  Methylated circulating tumor DNA in blood: power in cancer prognosis and response , 2016, Endocrine-related cancer.

[116]  Shuwen Liang,et al.  Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions: a systematic review and Meta-Analysis , 2016, Scientific Reports.

[117]  Chuanli Ren,et al.  Sox17 Promoter Methylation in Plasma DNA Is Associated With Poor Survival and Can Be Used as a Prognostic Factor in Breast Cancer , 2015, Medicine.

[118]  E. Lianidou,et al.  SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer , 2016, Clinical chemistry and laboratory medicine.

[119]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[120]  Yanjun Zeng,et al.  Quantitation of Plasma Circulating DNA Using Quantitative PCR for the Detection of Hepatocellular Carcinoma , 2012, Pathology & Oncology Research.

[121]  Niels Pallisgaard,et al.  Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma , 2013, Acta oncologica.

[122]  George A. Calin,et al.  Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer , 2004, Cancer Research.

[123]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[124]  Christopher M. Hindson,et al.  Absolute quantification by droplet digital PCR versus analog real-time PCR , 2013, Nature Methods.

[125]  I. Majsterek,et al.  Circulating Tumor Cells In Colorectal Cancer. , 2015, Polski przeglad chirurgiczny.

[126]  Claudia Peitzsch,et al.  Cancer biomarker discovery: Current status and future perspectives , 2014, International journal of radiation biology.

[127]  Valeri Vasioukhin,et al.  Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia , 1994, British journal of haematology.

[128]  S. Jeffrey,et al.  Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility , 2015, Clinical Cancer Research.

[129]  Mikko Niemi,et al.  Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 , 2013, Genome Medicine.

[130]  Stephan Beck,et al.  Methylome analysis using MeDIP-seq with low DNA concentrations , 2012, Nature Protocols.

[131]  A. Bardelli,et al.  Blood circulating tumor DNA for non‐invasive genotyping of colon cancer patients , 2016, Molecular oncology.

[132]  Timothy Hardy,et al.  Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease , 2016, Gut.

[133]  Christian Pilarsky,et al.  Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. , 2009, Clinical chemistry.

[134]  Lu Wen,et al.  Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients , 2015, Cell Research.

[135]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[136]  Sarah Webb,et al.  The cancer bloodhounds , 2016, Nature Biotechnology.

[137]  A. Giglio,et al.  Characterization of cell-free circulating DNA in plasma in patients with prostate cancer , 2013, Tumor Biology.

[138]  Zhe Zhang,et al.  Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. , 2014, Cancer research.

[139]  Saraswati Sukumar,et al.  Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients , 2012, International journal of cancer.

[140]  Johnny Lo,et al.  Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma , 2015, Oncotarget.

[141]  Olivier Elemento,et al.  Double-stranded DNA in exosomes: a novel biomarker in cancer detection , 2014, Cell Research.

[142]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[143]  Steven Q. Wang,et al.  Skin cancer: role of ultraviolet radiation in carcinogenesis , 2014, Reviews on environmental health.

[144]  Bela Molnar,et al.  DNA methylation biomarkers for blood-based colorectal cancer screening. , 2008, Clinical chemistry.

[145]  W F Bodmer,et al.  Beta-catenin mutations in cell lines established from human colorectal cancers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Peter Ulz,et al.  Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing , 2013, Genome Medicine.

[147]  Stefan Biesterfeld,et al.  Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis. , 2014, Cancer genomics & proteomics.

[148]  David Issadore,et al.  Issadore Micro-Hall Detector Ultrasensitive Clinical Enumeration of Rare Cells ex Vivo Using a , 2012 .

[149]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[150]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.

[151]  Paul Brown,et al.  The Cobas® EGFR Mutation Test v2 assay. , 2016, Future oncology.

[152]  A. Dricu,et al.  Methylation - From DNA, RNA and Histones to Diseases and Treatment , 2012 .

[153]  Daniela Massi,et al.  Multiparametric Analysis of Cell-Free DNA in Melanoma Patients , 2012, PloS one.

[154]  A W Preece.  Health Effects of Exposure to Low-Level Ionizing Radiation , 1996 .

[155]  R Montironi,et al.  Prostate tissue and serum markers. , 2000, Advances in clinical pathology : the official journal of Adriatic Society of Pathology.

[156]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[157]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[158]  Charles Swanton,et al.  Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine , 2014, Genome Biology.

[159]  Paul Cairns,et al.  Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients , 2004, Clinical Cancer Research.

[160]  S. Loi,et al.  Precision medicine for metastatic breast cancer—limitations and solutions , 2015, Nature Reviews Clinical Oncology.

[161]  Peter Ulz,et al.  Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing , 2014, PLoS genetics.

[162]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[163]  Anurag Srivastava,et al.  Clinical Significance of Promoter Hypermethylation of ERβ and RARβ2 in Tumor and Serum DNA in Indian Breast Cancer Patients , 2012, Annals of Surgical Oncology.

[164]  Anthony V D'Amico,et al.  Progress and controversies: Radiation therapy for prostate cancer , 2014, CA: a cancer journal for clinicians.

[165]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.

[166]  Hakan Akca,et al.  Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. , 2013, Cancer genetics.

[167]  Robert L Moritz,et al.  Exosomes: proteomic insights and diagnostic potential , 2009, Expert review of proteomics.

[168]  V. Vlassov,et al.  Deoxyribonuclease Activity and Circulating DNA Concentration in Blood Plasma of Patients with Prostate Tumors , 2008, Annals of the New York Academy of Sciences.

[169]  H. Boushey,et al.  Asthmatics with exacerbation during acute respiratory illness exhibit unique transcriptional signatures within the nasal mucosa , 2014, Genome Medicine.

[170]  Jia Fan,et al.  Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity , 2016, Journal of Cancer.

[171]  Mahmood Ayub,et al.  Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.

[172]  Se-Min Hwang,et al.  Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer , 2012, International Journal of Colorectal Disease.

[173]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[174]  Klaus Pantel,et al.  Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? , 2016, Clinical chemistry.

[175]  Peiyong Jiang,et al.  Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing , 2013, Proceedings of the National Academy of Sciences.

[176]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[177]  Thomas Rösch,et al.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer , 2013, Gut.

[178]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[179]  Zachary D. Smith,et al.  High-throughput bisulfite sequencing in mammalian genomes. , 2009, Methods.

[180]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[181]  J. Souverijn,et al.  Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.

[182]  E. Ma,et al.  Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments , 2015, Proceedings of the National Academy of Sciences.

[183]  Maarit Tiirikainen,et al.  Measurement of Circulating Cell‐Free DNA in Relation to 18F‐Fluorocholine PET/CT Imaging in Chemotherapy‐Treated Advanced Prostate Cancer , 2012, Clinical and translational science.

[184]  Georgia Sotiropoulou,et al.  DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. , 2011, Clinical chemistry.

[185]  Bo Dai,et al.  Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4 , 2012, Nature Genetics.

[186]  Apiwat Mutirangura,et al.  Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[187]  David Serre,et al.  MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome , 2009, Nucleic acids research.

[188]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[189]  Alexander Dobrovic,et al.  Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations , 2015, Scientific Reports.

[190]  Dong Soo Han,et al.  Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. , 2012, Oncology letters.

[191]  Eugene J. Lim,et al.  Microfluidic, marker-free isolation of circulating tumor cells from blood samples , 2014, Nature Protocols.

[192]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[193]  Sang Hyun Cho,et al.  Cancer Nanotechnology: Principles and Applications in Radiation Oncology , 2016 .

[194]  P. Vineis,et al.  Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. , 2007, Mutation research.

[195]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[196]  Yi Zhang,et al.  Enzymatic Incorporation of Multiple Dyes for Increased Sensitivity in QD‐FRET Sensing for DNA Methylation Detection , 2009, Chembiochem : a European journal of chemical biology.

[197]  Rebecca L. Siegel Mph,et al.  Colorectal cancer statistics, 2014 , 2014 .

[198]  Dong-Yeon Cho,et al.  DNA copy number evolution in Drosophila cell lines , 2014, Genome Biology.

[199]  Shengnan Jin,et al.  Measuring the methylome in clinical samples , 2012, Epigenetics.

[200]  M. Blute,et al.  Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. , 1999, The Journal of urology.